



0957-4166(94)00351-3


Synthesis of Enantiomerically Pure (1*S*, 2*R*)-Epoxy Indane and *cis*-(1*R*, 2*S*)-2-Amino-1-indanol.

Anton Mitrochkine [†], Franck Eydoux [†], Monique Martres [‡], Gérard Gil [‡],
Andreas Heumann [¶] and Marius Réglie ^{†*}.

[†] Laboratoire de Bioinorganique Structurale-URA CNRS 1409, C12; [‡] Laboratoire de Chimie Organique Biologique-URA CNRS 1409, 532; [¶] ENSSPICAM-URA CNRS 1410, Faculté des Sciences de Saint Jérôme, Avenue Escadrille Normandie-Niemen 13397 Marseille Cedex 20, France.

Abstract: Enantiomerically pure (1*S*, 2*R*)-epoxy indane and *cis*-(1*R*, 2*S*)-2-amino-1-indanol were synthesized via highly enantioselective lipase catalyzed transesterification of racemic *trans*-2-bromo-1-indanol.

Enantiomerically pure aminoindanol has recently been described as a highly efficient chiral ligand in titanium catalyzed asymmetric Diels Alder reactions¹ as well as a component of the inhibitor of a key enzyme in the human immunodeficiency virus (HIV).² Moreover, we have observed that 2-amino-1-indanol **5** as a metabolite³ of dopamine β -hydroxylase (DBH),⁴ a copper-containing monooxygenase which catalyses the transformation of dopamine into noradrenaline. In the course of these studies, the need for preparing useful quantities of enantiomerically active aminoindane **5** as well as the structurally related epoxy indane **4** became apparent. Both, epoxy indane **4** and aminoindanol **5** can easily be obtained from bromohydrin **1** that we envisioned to obtain in enantiomerically pure form. Enantiomerically pure bromohydrin **1** has been obtained by: 1) a combination of HPLC separation/crystallization techniques of menthylxyacetate diastereoisomers⁶ 2) microbial reduction of 2-bromo-1-indanone⁷ and 3) microbial hydrolysis of an acetate derivative.⁸ But in all cases, the enantiomeric excess was unsatisfactory and the transformation was inappropriate to large scale preparations of enantiomerically pure bromohydrin **1**.



We first studied the kinetic resolution of racemic *trans*-2-bromo-1-indanol **1** with different chiral carboxylic acids **6a-d** (ArOCHMeCOOH) derivatives of (*R*)-lactic acid, in the presence of dicyclohexyl carbodiimide (DCC) and catalytic amounts of 4-dimethylaminopyridine (DMAP) in THF at room temperature.⁹ This reaction led to a mixture of the corresponding esters **3a-d** and the remaining bromohydrin **1** (Table 1), but unfortunately, the enantiomeric excess of remaining bromohydrin **1** did not exceed 15% (diastereoisomeric excess of esters **3a-d**: 24%).

Table 1. Kinetic resolution of racemic *trans*-bromohydrin **1** with chiral carboxylic acids **6a-d** (2:1 molar ratio).

| Acids 6a-d | Esters 3a-d | | Bromohydrin 1 | | | |
|-------------------------------|---------------------|---------------------|----------------------|----------------------|-------------------|----------------------------|
| | Yields ⁱ | d. e. ⁱⁱ | Yields ⁱ | e. e. ⁱⁱⁱ | $[\alpha]_D^{25}$ | Config. ^{iv} |
| 6a (Ar = 4-Cl-2-Me-Ph) | 88% | 24% | 80% | 14% | + 8.1 | (1 <i>S</i> , 2 <i>S</i>) |
| 6b (Ar = 4-F-2-I-Ph) | 78% | 17% | 81% | 10% | + 5.8 | (1 <i>S</i> , 2 <i>S</i>) |
| 6c (Ar = 4-F-2-Cl-Ph) | 90% | 20% | 75% | 15% | + 8.5 | (1 <i>S</i> , 2 <i>S</i>) |
| 6d (Ar = 4-F-2-Br-Ph) | 85% | 16% | 89% | 13% | + 8.0 | (1 <i>S</i> , 2 <i>S</i>) |

ⁱ) Based on the starting carboxylic acid **6a-d**. ⁱⁱ) Determined by ¹H NMR spectroscopy. ⁱⁱⁱ) Determined by HPLC using Chiralcel column OD-H (Daicel) with hexane/isopropyl alcohol (99:1) as eluant. ^{iv}) From the $[\alpha]_D^{25} = -64.4$ in EtOH for (1*R*, 2*R*) enantiomer (Ref. 6).

The use of hydrolytic enzymes as catalysts for asymmetric hydrolysis has been well documented.¹⁰ A preparative method using the kinetic resolution of racemic acetates **2** with four different lipases was now considered (Table 2). Unfortunately, even after two days in a phosphate buffer (*pH* = 7.5) the conversion and enantiomeric excess were very poor (< 5%). Next we used the lipase in a transesterification process with vinyl acetate as acyl donor.¹¹ As shown in figure 1 and table 2, after 8 days for 80% conversion, LP 237.87 lipase gave satisfactory and reproducible results which gave (1*S*, 2*S*)-bromohydrin **1** in extremely enantiomerically pure form (e. e. > 99%). When the reaction was stopped after 1 day (15% conversion) (1*R*, 2*R*)-acetate **4** was obtained with 70% enantiomeric purity.





Figure 1. Kinetic resolution of racemic *trans*-bromohydrin **1** with lipases.

Table 2. Lipase catalyzed transesterification of racemic *trans*-bromohydrin **1**.


| Lipases | Reaction Times in days | Acetate 4 | | | Bromohydrin 1 | | | | |
|-------------------------------------|------------------------|---------------------|-------------------|----------------------------|----------------------|---------------------|-------------------|----------------------------|---------------------|
| | | Yields ⁱ | $[\alpha]_D^{25}$ | Config. ⁱⁱ | e. e. | Yields ⁱ | $[\alpha]_D^{25}$ | Config. ⁱⁱⁱ | e. e. ^{iv} |
| LCC | 10 | 58% | -51 | (1 <i>R</i> , 2 <i>R</i>) | 30% | 38% | +11.8 | (1 <i>S</i> , 2 <i>S</i>) | 20% |
| <i>P. fluorescens</i> ^{vi} | 10 | 62% | -53 | (1 <i>R</i> , 2 <i>R</i>) | 32% | 35% | +15 | (1 <i>S</i> , 2 <i>S</i>) | 30% |
| LPP | 10 | 58% | -55 | (1 <i>R</i> , 2 <i>R</i>) | 33% | 39% | +12.6 | (1 <i>S</i> , 2 <i>S</i>) | 20% |
| LP 237.87 ^{vii} | 8 | 77% | -32 | (1 <i>R</i> , 2 <i>R</i>) | 19% | 20% | +57.8 | (1 <i>S</i> , 2 <i>S</i>) | > 99% |
| LP 237.87 | 1 | 13% | -117 | (1 <i>R</i> , 2 <i>R</i>) | 70% | 87% | +6.2 | (1 <i>S</i> , 2 <i>S</i>) | 13% |

ⁱ) Yields based on isolated products after flash chromatography. ⁱⁱ) From the $[\alpha]_D^{25} = -167.5$ in EtOH for (1*R*, 2*R*) enantiomer (Ref. 6). ⁱⁱⁱ) From the $[\alpha]_D^{25} = -64.4$ in EtOH for (1*R*, 2*R*) enantiomer (Ref. 6). ^{iv}) Determined by HPLC using Chiralcel column OD-H (Daicel) with hexane/isopropyl alcohol (99:1) as eluant. ^{vi}) Amano. ^{vii}) Gist Brocades.



(1*S*, 2*R*)-Epoxy indane **4** was obtained in good yields (85%) and high enantiomeric excess (95.5%, determined by GLC at 120°C on a Macherey Nagel Lipodex A column) by reaction of *trans*-(1*S*, 2*S*)-2-bromo-1-indanol **1** with sodium methylate in THF (25°C, 2 h).¹² By the same way, *trans*-(1*R*, 2*R*)-1-acetoxy-2-bromo-indane **2** was converted into enantiomeric (1*R*, 2*S*)-epoxy indane **4**. By treatment with NaN₃ in DMF, *trans*-(1*S*, 2*S*)-2-bromo-1-indanol **1** was transformed into enantiomerically pure *cis*-(1*S*, 2*R*)-2-azido-1-

indanol **7** in 76% yield and > 99% e. e. (determined by HPLC on Daicel Chiralcel column OD-H with hexane/isopropyl alcohol (99:1) as eluant).¹ Hydrogenation catalyzed by palladium on charcoal gave *cis*-(1*S*, 2*R*)-2-amino-1-indanol **5** in 78% overall yield and > 99% e.e. The direct S_N2 azidation of the bromoacetate **2** (**2** ⇒ **8**) instead of bromohydrin **1** was less selective since the S_N2 process is in competition with the formation of cationic oxonium ion **11**. Nucleophilic attack of **11** lead to a mixture of *trans* azido acetate **9** and **10** (total 42%) as side products with retention of configuration.



In summary, enantioselective lipase catalyzed transesterification of indane bromohydrin provides epoxy indanes **4** and *cis*-(1*S*, 2*R*)-2-amino-1-indanol **5** in good yields and high enantiomeric excess complementary to the chemical resolution of racemic *cis*-2-amino-1-indanol **5** which gives the opposite enantiomer (1*S*, 2*R*).

Acknowledgment: We are grateful to C. N. R. S. for financial support, IPSEN-I. H. B. and the IMABIO program for a BDI scholarship to F. Eydoux and the French Government for a grant to A. Mitrochkine.

References and Notes:

- Corey, E. J.; Roper, T. D.; Ishihara, K.; Sarakinos, G. *Tetrahedron Letters* **1993**, *34*, 8399.
- Moon Kim, B.; Guare, J. P.; Hanifin, C. M.; Arford-Bickerstaff, D. J.; Vacca, J. P.; Ball, R. G. *Tetrahedron Letters* **1994**, *35*, 5153.
- Eydoux, F.; Réglie M. to be published.
- Klinman, J. P. *Ann. Rev. Biochem.* **1988**, *57*, 551.
- Compound **4** is a DBH inhibitor; Eydoux F. Ph. D. thesis, Marseille, **1993**.
- Boyd, D. R.; Sharma, N. D.; Smith A. E. *J. Chem. Soc. Perkin Trans. I* **1982**, 2767.
- Imuta, M.; Ziffer H. *J. Org. Chem.* **1978**, *43*, 4540.
- Kawai, K-I.; Imuta, M.; Ziffer H. *Tetrahedron Letters* **1981**, *22*, 2527.
- Chinchilla, R.; Najera, C.; Yus M.; Heumann A. *Tetrahedron: Asymmetry* **1990**, *1*, 851. Chinchilla, R.; Najera, C.; Yus M.; Heumann A. *Tetrahedron: Asymmetry* **1991**, *2*, 101. Mazon, A.; Najera, C.; Yus M.; Heumann A. *Tetrahedron: Asymmetry* **1992**, *3*, 1455.
- Chen, C. S.; Sih, C. J. *Angew. Chem. Int. Ed. Eng.* **1989**, *28*, 695. Boland, W.; Frössl, C.; Lorenz, M. *Synthesis* **1991**, 1049.
- Faber, K.; Riva, S. *Synthesis* **1992**, 895.
- Akhtar, M. N.; Boyd, D. R.; Hamilton J. G. *J. Chem. Soc. Perkin Trans. I*, **1979**, 2437.

(Received in UK 20 September 1994)